血浆源性因子VIII/血管性血友病因子(FVIII/VWF)与艾美赛珠单抗体外联用对凝血酶生成的效应不叠加
本研究在体外将含血管性血友病因子的血浆源性因子VIII浓缩物(pdFVIII/VWF)加入伴或不伴抑制物的A型血友病血浆,并联合不同浓度艾美赛珠单抗。结果显示pdFVIII/VWF与艾美赛珠单抗联用对凝血酶生成的效应不叠加,作者认为这提示艾美赛珠单抗在pdFVIII/VWF存在时促进因子X活化的能力有限。
要点
- pdFVIII/VWF加入含艾美赛珠单抗的A型血友病血浆后,凝血酶生成反应与不含艾美赛珠单抗的样本等效。
- 活化的凝血酶原复合物加入含艾美赛珠单抗的A型血友病血浆后,凝血酶生成大幅增加(倍增效应>4.5×)。
- pdFVIII/VWF与艾美赛珠单抗体外联用对凝血酶生成呈非叠加效应。
核心结论
- pdFVIII/VWF与艾美赛珠单抗体外联用对凝血酶生成呈非叠加效应,作者认为这提示艾美赛珠单抗在pdFVIII/VWF存在时促进因子X活化的能力有限,从而可能降低血栓事件风险。
研究设计与样本
- 体外研究:将含血管性血友病因子的血浆源性因子VIII浓缩物加入伴或不伴抑制物的A型血友病血浆,并联合不同浓度艾美赛珠单抗。
- 艾美赛珠单抗浓度为50和100 μg/mL,活化的凝血酶原复合物为0.5至1 U/mL,重组活化因子VII为0.5至7 μg/mL,pdFVIII/VWF为0.1至4.5 IU/mL。
- 采用校准自动凝血酶生成图测定凝血酶生成(凝血酶峰值与内源性凝血酶潜能)。
主要发现
- 活化的凝血酶原复合物加入含艾美赛珠单抗的伴或不伴抑制物A型血友病血浆后,凝血酶生成大幅增加,倍增效应>4.5×。
- 重组活化因子VII加入含艾美赛珠单抗的伴或不伴抑制物A型血友病血浆后,凝血酶生成呈浓度相关的适度增加,与单用重组活化因子VII相比。
- pdFVIII/VWF加入含艾美赛珠单抗的伴或不伴抑制物A型血友病血浆后,凝血酶生成反应与不含艾美赛珠单抗的样本等效。
- 在模拟伴出血的免疫耐受诱导体外模型(A型血友病血浆伴抑制物15 Bethesda单位)中,pdFVIII/VWF、艾美赛珠单抗与重组活化因子VII联用未触发凝血酶生成的倍增效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emicizumab is an alternative non-factor approach for treating patients with hemophilia A. However, there is a potential risk of thrombotic events when emicizumab is concomitantly administered with pro-hemostatic therapies. OBJECTIVES: To assess the hemostatic effect in vitro when a plasma-derived factor VIII concentrate containing von Willebrand factor (pdFVIII/VWF) was added to hemophilia A plasma (HAp) in combination with emicizumab. METHODS: HAp and HAp with FVIII inhibitors (HAp-i) samples with different concentrations of emicizumab (50 and 100 μg/mL) were combined with activated prothrombin complex concentrate at 0.5 to 1 U/mL, recombinant activated factor VII (rFVIIa) at 0.5 to 7 μg/mL, and pdFVIII/VWF at 0.1 to 4.5 IU/mL. Thrombin generation (TG; thrombin peak and endogenous thrombin potential) was determined using a Calibrated Automated Thrombogram assay. RESULTS: When activated prothrombin complex concentrate was added to HAp and HAp-i with emicizumab, TG dramatically increased (multiplier effect > 4.5×). Addition of rFVIIa to HAp or HAp-i with emicizumab moderately increased TG in a concentration-related manner compared with rFVIIa alone. Addition of pdFVIII/VWF to HAp or HAp-i with emicizumab induced a TG response equivalent to those samples without emicizumab. In an in vitro model of immune tolerance induction with bleeds (HAp-i 15 Bethesda units), combination of pdFVIII/VWF, emicizumab, and rFVIIa did not trigger a multiplying effect on TG. CONCLUSIONS: pdFVIII/VWF showed a non-additive effect on TG when combined in vitro with emicizumab. This finding suggests that emicizumab has limited ability to promote factor X activation in the presence of pdFVIII/VWF, thus reducing the risk of thrombotic events.
引用
- Bravo MI, Raventós A, Pérez A, et al. Non-additive effect on thrombin generation when a plasma-derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro. J Thromb Haemost. 2020. PMID: 32379931. doi:10.1111/jth.14887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。